Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Brozos-Vázquez, Elena; Toledano-Fonseca, Marta; Costa-Fraga, Nicolás; García-Ortiz, María Victoria; Díaz-Lagares, Ángel; Rodríguez-Ariza, Antonio; Aranda, Enrique; López-López, Rafael

doi:10.1016/j.ctrv.2024.102719

Cited by 4 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, tumors eventually recur, highlighting the need for a combination of more effective therapies with immune checkpoint inhibitors for sustained tumor regression and improved survival [91]. Pancreatic cancer patients without KRAS mutations exhibit other actionable genetic alterations, such as MSI/dMMR, BRAF mutations, and kinase-fusion genes, emphasizing the role of precision oncology in identifying potential targets for tailored treatments [92].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Cortiana,

Abbas,

Chorya

et al. 2024

Cancers

View full text Add to dashboard Cite

Pancreatic cancer, with its alarming rising incidence, is predicted to become the second deadliest type of solid tumor by 2040, highlighting the urgent need for improved diagnostic and treatment strategies. Despite medical advancements, the five-year survival rate for pancreatic cancer remains about 14%, dropping further when metastasized. This review explores the promise of biomarkers for early detection, personalized treatment, and disease monitoring. Molecular classification of pancreatic cancer into subtypes based on genetic mutations, gene expression, and protein markers guides treatment decisions, potentially improving outcomes. A plethora of clinical trials investigating different strategies are currently ongoing. Targeted therapies, among which those against CLAUDIN 18.2 and inhibitors of Claudin 18.1, have shown promise. Next-generation sequencing (NGS) has emerged as a powerful tool for the comprehensive genomic analysis of pancreatic tumors, revealing unique genetic alterations that drive cancer progression. This allows oncologists to tailor therapies to target specific molecular abnormalities. However, challenges remain, including limited awareness and uptake of biomarker-guided therapies. Continued research into the molecular mechanisms of pancreatic cancer is essential for developing more effective treatments and improving patient survival rates.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Cortiana,

Abbas,

Chorya

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy

Hu,

Guo,

et al. 2024

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Redefining pancreatic cancer management with tumor-agnostic precision medicine

Reddy,

Subbiah

2024

Carcinogenesis

View full text Add to dashboard Cite

Precision oncology and tumor-agnostic drug development provide hope for enhancing outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged across various tumor types, driven by insights into shared biomarkers. In the case of pancreatic cancer, the prevalence of the KRAS gene mutation is noteworthy. However, there exist other actionable alterations, such as BRCA1/2 mutations and fusion genes (BRAF, FGFR2, RET, NTRK, NRG1, and ALK), which present potential targets for therapy. Notably, tumor-agnostic drugs have demonstrated efficacy in specific subsets of pancreatic cancer patients who harbor these genetic alterations. Despite the rarity of NTRK fusions in pancreatic cancer, larotrectinib and entrectinib have exhibited effectiveness in NTRK fusion-positive pancreatic cancers. Additionally, repotrectinib, a next-generation NTRK inhibitor, has shown promising activity in NTRK positive pancreatic cancer patients who have developed acquired resistance to previous NTRK inhibitors. Immune checkpoint inhibitors, such as pembrolizumab and dostarlimab, have proven to be effective in dMMR/MSI-H pancreatic cancers. Moreover, targeted therapies for BRAF V600, RET fusions, and HER2/neu overexpression have displayed promising results in specific subsets of pancreatic cancer patients. Emerging targets like NRG fusions, FGFR2 fusions, TP53 mutations, and KRAS G12C mutations present potential avenues for targeted therapy. Tumor-agnostic therapies have the potential to revolutionize pancreatic cancer treatment by focusing on specific genetic alterations. It is crucial to continue implementing comprehensive screening strategies that encompass the ability to detect all these tumor-agnostic biomarkers. This will be essential in identifying pancreatic cancer patients who may benefit from these therapies.

show abstract

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Cited by 4 publications

References 71 publications

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy

Redefining pancreatic cancer management with tumor-agnostic precision medicine

Contact Info

Product

Resources

About